
2 population and in individuals with major depressive disorder

- Olli Kärkkäinen^{a, *}, Tommi Tolmunen^{b,c}, Petri Kivimäki^{b,d}, Karoliina Kurkinen^b, Toni Ali-4
- Sisto^b, Pekka Mäntyselkä^{e,f}, Minna Valkonen-Korhonen^{b,g}, Heli Koivumaa-Honkanen^b, Kirsi 5
- Honkalampi^h, Anu Ruusunen^{e,g,i}, Vidya Velagapudi^j, Soili M. Lehto^{k,l,m} 6
- ^a School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland 8
- ^b Institute of Clinical Medicine/Psychiatry, University of Eastern Finland, P.O. Box 1627, 9
- 70211, Kuopio, Finland 10
- ^c Department of Adolescent Psychiatry, Kuopio University Hospital, P.O. Box 100. 70029 11
- KYS, Finland 12

3

7

- ^d City of Helsinki, Vuosaari Outpatient Psychiatry Clinic. Postal address: P.O. Box 6250, FI-13
- 00099 City of Helsinki, Helsinki, Finland 14
- ^e Clinical Research and Trials Centre, Kuopio University Hospital, P.O. Box 100. 70029 15
- KYS, Finland 16
- f Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 17
- 1627, 70211, Kuopio, Finland 18
- 19 g Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland
- ^h School of Educational Sciences and Psychology, University of Eastern Finland, P.O. Box 20
- 111, 80101 Joensuu. Finland 21
- ¹ Deakin University, IMPACT the Institute for Mental and Physical Health and Clinical 22
- Translation, Food & Mood Centre, IMPACT Strategic Research Centre, School of Medicine, 23
- 24 P.O. Box 281, Geelong, VIC 3220, Australia
- ^j Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, P.O. Box 20, FI-25
- 00014 University of Helsinki, Finland 26 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.



Keywords: Depression; Alcoholism; Metabolomics; Hippurate; 5-hydroxyindoleacetic acid

38

ABSTRACT

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

Our aim was to evaluate whether alcohol use is associated with changes in the circulating metabolite profile similar to those present in persons with depression. If so, these findings could partially explain the link between alcohol use and depression. We applied a targeted liquid chromatography mass spectrometry method to evaluate correlates between concentrations of 86 circulating metabolites and self-reported alcohol use in a cohort of the non-depressed general population (GP) (n = 247) and a cohort of individuals with major depressive disorder (MDD) (n = 99). Alcohol use was associated with alterations in circulating concentrations of metabolites in both cohorts. Our main finding was that selfreported alcohol use was negatively correlated with serum concentrations of hippuric acid in the GP cohort. In the GP cohort, consumption of six or more doses per week was associated with low hippuric acid concentrations, similar to those observed in the MDD cohort, but in these individuals it was regardless of their level of alcohol use. Reduced serum concentrations of hippuric acid suggest that already moderate alcohol use is associated with depression-like changes in the serum levels of metabolites associated with gut microbiota and liver function; this may be one possible molecular level link between alcohol use and depression.

perpetuity.

It is made available under a CC-BY 4.0 International license.

Introduction

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Heavy alcohol use and lifetime occurrence of alcohol use disorder have been associated with an increased incidence of a major depressive disorder (MDD) (Grant et al., 2015; McHugh & Weiss, 2019; Odlaug et al., 2016). It has been estimated that around one in six of persons with MDD is suffering from a current alcohol use disorder, and that around every third person with MDD has had a lifetime occurrence of alcohol use disorder (DeVido & Weiss, 2012; Sullivan et al., 2005; Swendsen et al., 1998). However, the relationship between moderate alcohol use and the incidence of MDD remains controversial: some studies show possible small increase in the incidence of MDD (Odlaug et al., 2016), whereas others have not been able to detect any associations (García-Esquinas et al., 2018) or even found evidence for a reduced incidence of MDD (Bellos et al., 2016). Light alcohol use has not been associated with an increased risk of MDD, and light drinkers are commonly used as controls in these studies (Bellos et al., 2016; García-Esquinas et al., 2018; Grant et al., 2015; Odlaug et al., 2016). One possible mediating effect between alcohol use and MDD are changes in the activity of many metabolic processes. Heavy alcohol use has been associated with an altered metabolome (for a review see Voutilainen and Kärkkäinen, 2019). For example, increased levels of glutamate, citrate, alanine, phenylalanine, tyrosine, glucose, docosahexaenoate, 2piperidone and phosphatidylcholine diacyls, and decreased levels of glutamine, serotonin, asparagine, hydroxysphingomyelins, gamma-aminobutyric acid (GABA) and phosphatidylcholine acyl-alkyls have been associated with heavy alcohol use (Heikkinen et al., 2019; Jaremek et al., 2013; Kärkkäinen, Farokhnia, et al., 2021; Kärkkäinen, Kokla, et al., 2021; Lehikoinen et al., 2018; Würtz et al., 2016). In a prospective study with an over 30

81

82

83

84

85

86

87

88

89

90

91

92

93

MDD.

5

years' follow-up, changes in the circulating metabolome, e.g., decreased levels of serotonin and asparagine, preceded the diagnosis of diseases related to alcohol use (Kärkkäinen et al., 2020). Similarly, also MDD has been associated with alterations in circulating levels of metabolites – some of which have also been linked to alcohol use (e.g., glutamate, phenylalanine, citrate and serotonin; for a review see Gadad et al., 2018). This evidence, in addition to the observed overlap in the incidences of MDD and alcohol use, imply that there may well be some shared underlying pathology related to the disturbances in metabolic processes. We have now investigated whether alcohol use would be associated with similar changes in the circulating metabolite profiles irrespective of the presence of depression by measuring the associations between serum metabolite concentrations and self-reported alcohol use in two

cohorts: a non-depressed general population (GP) cohort and a cohort of individuals with

perpetuity.
It is made available under a CC-BY 4.0 International license.

Material and methods

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

Study cohorts Two cohorts were used: 1) a general population cohort of non-depressed individuals (GP cohort), and 2) patients with major depressive disorder (MDD cohort) (Ali-Sisto et al., 2016; Kraav et al., 2019). Both cohorts represented the same population, as Kuopio University Hospital from where the MDD cohort was recruited serves the municipality area of Lapinlahti from where the GP cohort was recruited. The Ethics Committee of Hospital District of Northern Savo approved both studies. Participants provided written informed consent before entering the studies. The non-depressed GP cohort was from a population-based follow-up study consisting of 480 individuals living in the municipality area of Lapinlahti, Finland in 2005. The sample described here was collected as a part of a 5-year follow-up of the study in 2010 (n = 326) but only participants with alcohol use data (n = 289). Further exclusion criteria were a) Beck Depression Inventory (BDI) score of ≥ 10 at the time of the study or 5 years earlier (Beck, 1961), or b) use of medication for depression. After exclusions, a total of 247 subjects were included in the study (Table 1). The MDD cohort consisted of 99 outpatients with MDD who were recruited from the Department of Psychiatry of Kuopio University Hospital, Finland. The diagnosis of MDD was confirmed with the structured clinical interview for DSM-IV (SCID) (DSM-IV; American Psychiatric Association, 1994). The exclusion criteria were a) bipolar disorder, b) psychotic disorders, c) a symptomology of mental illness due to alcohol or substance abuse-

related diagnosis, d) epilepsy, and e) current somatic conditions preventing participation in

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

7

use of fruits (< 1 time/week, 1-5 times/week, > 5 times/week, according to Savolainen et al.

2014), and body mass index (BMI) were only available in the GP cohort.

perpetuity.

It is made available under a CC-BY 4.0 International license.

Metabolite profiling analysis

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Venous blood samples were obtained via venipuncture by trained laboratory personnel and centrifuged to separate the serum. Before venipuncture, the participants were instructed to fast for 12 hours. Serum samples were stored frozen at -80 °C until analyzed. The samples were analyzed in the metabolomics unit of the Institute of Molecular Medicine Finland (FIMM) in Helsinki, Finland. Metabolite profiling analysis of the samples was performed using liquid chromatography-mass spectrometry. Briefly, 10 µL of labeled internal standard mixture was added to the 100 µL of samples, and the samples were allowed to equilibrate with the internal standards. A total of 400 µL of extraction solvent (1% formic acid in acetonitrile) was added and the collected supernatant was dispensed into an OstroTM 96-well plate (Waters Corporation, Milford, USA) and then filtered by applying a vacuum at a delta pressure of 300-400 mbar for 2.5 minutes on a Hamilton robot's vacuum station. After this, 5 μL of filtered sample extract was injected into an Acquity UPLC system coupled to a Xevo® TQ-S triple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA), which was operated in both positive and negative polarities with a polarity switching time of 20 msec for metabolite separation and quantification. The Multiple Reaction Monitoring (MRM) acquisition mode was selected for the quantification of the metabolites. MassLynx 4.1 software was used for data acquisition, data handling, and instrument control. The data were processed using TargetLynx software.

Statistics

In the comparison of the background characteristics of the cohorts, we used Mann-Whitney U test for continuous and χ^2 test for binomial variables.

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

For the metabolite profiling data, only metabolites that were above the quantification limits in at least 50% of subjects in at least one cohort were included in the study. Metabolite concentrations below the quantification limit were excluded from the analysis, with the exception of cotinine, where concentrations below the quantification limit were considered to be zero.

In the statistical analysis of the metabolite data, the self-reported weekly alcohol drinking levels were coded numerically (1 = < 1 drink/week, 2 = 1-2 drink(s)/week, 3 = 3-5)drinks/week, 4 = 6–9 drinks/week, 5 = 10–14 drinks/week, 6 = 15–21 drinks/week, 7 = 22–28 drinks/week, and 8 = 28 drinks/week) to allow us to conduct a regression analysis. We analyzed the two cohorts separately for changes in the metabolite concentrations associated with alcohol use. This was done to focus the analysis on alcohol use related changes, not to changes associated with MDD, which have been reported earlier (Ali-Sisto et al. 2016). We used linear regression to investigate correlations between self-reported weekly alcohol drinking and serum metabolite concentrations. To account for multiple testing, we undertook a principal component analysis and used the number of principal components needed to explain 95% of variance in the datasets to adjust the α-level using Bonferroni's method to 0.001 (46 and 41 principal components were needed to explain 95% of variance in the GP and MDD cohorts, respectively). Metabolites with p-values between 0.05 and 0.001 were considered as trends.

For metabolites with a p-value below 0.05 in the initial analysis, we conducted a post-hoc analysis using linear regression with possible confounders previously associated with alcohol

189 use and/or metabolite levels (age, sex, use of vegetables, use of fruits, smoking, BMI, education level, and cohabitation status) as covariates. We used JASP (version 0.14), SIMCA 190 (version 17, Umetrics), and Prism (GraphPad Software Inc., version 7) for statistical 191 192 analyses, multivariate analysis, and figure preparation, respectively.

Results

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

The characteristics of the study participants in both cohorts are presented in Table 1. The GP cohort was older than the MDD cohort. With respect to the selection criteria, as would be expected, the MDD cohort had higher BDI scores when compared to the non-depressed GP cohort. Subjects in the MDD cohort were living alone and smoked regularly more often when compared to the GP cohort.

The correlations found between self-reported alcohol use and serum metabolite concentrations with p-value below 0.05 in at least one cohort are shown in Figure 1. However, at the multiple testing adjusted α level of 0.001, the only significant correlations were observed between self-reported alcohol use and serum concentrations of hippuric acid and chenodeoxycholic acid in the GP cohort, and xanthosine in the MDD cohort (Figure 1). Correlations with p-values between 0.05 and 0.001 should be considered as trends that need to be validated in larger cohorts. The correlations between self-reported alcohol use and all 86 measured metabolites are shown in the Supplementary Table 1.

A post-hoc analysis was conducted using linear regression with potential confounders. In the GP cohort, most of the correlations between self-reported alcohol use and metabolite levels remained significant after taking into account possible confounders (hippuric acid $\beta = -0.19$, p = 0.0037; chenodeoxycholic acid $\beta = 0.19$, p = 0.0049; cytidine $\beta = 0.22$, p = 0.0011; 5-HIAA $\beta = -0.16$, p = 0.0183; taurocholic acid $\beta = 0.22$, p = 0.0012; glutamine $\beta = -0.20$, p = 0.0040; and serine $\beta = -0.16$, p = 0.0218). There were two exceptions; glycine ($\beta = -0.12$, p =0.0785) and cotinine ($\beta = 0.03$, p = 0.5005). Instead of alcohol use, sex correlated more with the glycine concentration ($\beta = -0.15$ and p = 0.0382) and smoking status more with cotinine

concentrations ($\beta = 0.74$, p < 0.0001). In the MDD cohort, all metabolites with a p-value 217 below 0.05 in the initial analysis also had a p-value below 0.05 in the linear regression 218 models when lifestyle factors were included as covariates (xanthosine $\beta = -0.38$, p = 0.0002; 219 GABA $\beta = 0.25$, p = 0.0186; cytidine $\beta = 0.21$, p = 0.0388; carnosine $\beta = -0.21$, p = 0.0348; 220 and 2-aminoisobutyric acid $\beta = 0.22$, p = 0.0336). 221

Discussion

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Our main finding was that in the GP cohort, at least moderately increased alcohol use was associated with lower serum concentrations of hippuric acid. The hippuric acid concentrations in those individuals who reported six or more alcohol doses per week were similar to the concentrations observed in the MDD cohort regardless of their level of alcohol use (Figure 1). These results are in line with previous reports, where decreased levels of hippuric acid have been associated with alcohol use, depression, anxiety disorders, and stress (J. Chen et al., 2018; Kärkkäinen et al., 2020; Phua et al., 2015; P. Zheng, Wang, et al., 2013; P. Zheng, Chen, et al., 2013). Although rather little is known to explain how hippuric acid might influence behavior, previous studies have found that low hippuric acid levels may impair neuronal development in fetal mouse brain (Ahmed et al., 2022; Vuong et al., 2020). Moreover, in humans, low serum hippuric acid concentrations have been associated with mild cognitive impairment, whereas high levels of hippuric acid have been linked with beneficial effects on cognitive performance (Rutledge et al., 2021; Yilmaz et al., 2020). In the GP cohort, similar trends were also seen in the association between self-reported alcohol use and concentrations of 5-HIAA and histidine. Interestingly, the composition of gut microbiota may influence the serum levels of the following three compounds, i.e., hippuric acid (Behr et al., 2017; Fujisaka et al., 2018; Lees et al., 2013; Pessa-Morikawa et al., 2022; Vuong et al., 2020; Williams et al., 2010), 5-HIAA (Lukić et al., 2019), and histidine (H. Chen et al., 2019; Kawase et al., 2017). Moreover, both alcohol use and MDD have been associated with an altered composition and changes in the function of the gut microbiota (Kelly et al., 2016; Leclercq et al., 2014; Llopis et al., 2016; Winter et al., 2018; P. Zheng et

al., 2016). Therefore, alterations in the gut microbiota could explain the correlations between serum levels of these metabolites, alcohol use and depression.

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

However, in the case of hippuric acid, the gut microbiota first makes benzoic acid from phenolic compounds in the diet, and then the liver forms hippuric acid by combining benzoic acid with glycine (Lees et al., 2013). The declines in serum hippuric acid concentrations could therefore also be a reflection of disturbed liver function since decreased hippuric acid production has been associated with alcohol use and impaired liver function (van Sumere et al., 1969). Furthermore, the intake of vegetables or fruits, the main sources of phenolic compounds in the diet, did not significantly correlate with serum hippuric acid concentrations in the present study. Therefore, differences in the intakes of food items with phenolic compounds are not a likely explanation for the changes we observed in serum levels of hippuric acid. More research is needed to clarify the role of hippuric acid in alcohol use and depression.

Moreover, we also observed a positive correlation between self-reported alcohol consumption and serum concentrations of two bile acids, chenodeoxycholic acid and taurocholic acid. These correlations could be associated with altered bile acid synthesis or metabolism, which can also be linked with the gut microbiota (Bajaj, 2019). Increases in serum levels of bile acids have been associated with the organ damage induced by alcohol consumption (Bajaj, 2019; Milstein et al., 1976; Trinchet et al., 1994). Interestingly, there was no correlation between self-reported alcohol use and chenodeoxycholic acid levels in the MDD cohort, which could be associated with altered cholesterol metabolism in MDD since cholesterol is a starting precursor for bile acid formation (Kraav et al., 2019; Lehto et al., 2010). Moreover,

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

in the MDD cohort, we observed a negative correlation between xanthosine and self-reported alcohol use, which was not observed in the GP cohort. This difference is likely linked to the previously reported dysregulation of purine metabolism in the same cohort (Ali-Sisto et al., 2016). Furthermore, there were several metabolites, which were positively (cytidine, taurocholic acid) or negatively (glycine, serine and glutamine) correlated with self-reported alcohol use in both the GP and MDD cohorts with similar standardized β coefficients (Figure 1). However, due to the smaller sample size, these correlations were not statistically significant in the MDD cohort. These alterations are in line with results from previous studies investigating changes associated with alcohol use in the human circulating metabolome (Kärkkäinen et al., 2020; Lehikoinen et al., 2018; Voutilainen & Kärkkäinen, 2019; Würtz et al., 2016). Limitations of the study include the relatively small number of subjects in the MDD cohort. Based on the present results, moderate alcohol use seems to be associated with small-tomedium effect size changes in the serum metabolite profile and therefore future studies should examine larger cohorts. We estimated that a sample size of 315 would be needed to observe small-to-medium effect size ($f^2 > 0.1$) correlations between alcohol use and metabolite concentrations with the corrected α level used in the present study (0.0001) with 0.95 statistical power. Furthermore, future studies should also use other biomarkers such as phosphatidylethanols, to assess recent alcohol use instead of relying solely on self-reporting (Y. Zheng et al., 2011).

294

295

296

297

298

16

The present results show that already moderate alcohol use is associated with depression-like changes in the serum levels of a metabolite, hippuric acid, which has been linked with both the gut microbiota and liver function. This indicates that changes in the metabolites associated with the gut microbiota and liver function could be one of the molecular level links between alcohol use and depression, although further research will be needed to verify this hypothesis.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

17

Funding source This work was supported by The Finnish Foundation for Alcohol Studies (OK), and the Finnish Medical Foundation (SML). **Declaration of competing interest** OK is a co-founder of Afekta Technologies Ltd., company providing metabolomics analysis services (not used in the present study). All other authors have no conflicts of interest to declare. Acknowledgements The authors wish to thank Dr. Jorma Savolainen for his significant contribution in the collection of the Lapinlahti Study sample, and Dr. Ewen MacDonald for proofreading. Data availability statement The data that support the findings of this study are available on request from the corresponding author, OK. The data are not publicly available due to their containing information that could compromise the privacy of research participants. The study plan approved by the ethical committee and the participant consent terms preclude public sharing of these sensitive data, even in anonymized form.

References

318

319	Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022).
320	Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes, 14(1),
321	2102878. https://doi.org/10.1080/19490976.2022.2102878
322	Ali-Sisto, T., Tolmunen, T., Toffol, E., Viinamäki, H., Mäntyselkä, P., Valkonen-Korhonen, M.,
323	Honkalampi, K., Ruusunen, A., Velagapudi, V., & Lehto, S. M. (2016). Purine metabolism is
324	dysregulated in patients with major depressive disorder. Psychoneuroendocrinology, 70, 25–
325	32. https://doi.org/10.1016/j.psyneuen.2016.04.017
326	Bajaj, J. S. (2019). Alcohol, liver disease and the gut microbiota. <i>Nature Reviews. Gastroenterology</i> &
327	Hepatology, 16(4), 235–246. https://doi.org/10.1038/s41575-018-0099-1
328	Beck, A. T. (1961). An Inventory for Measuring Depression. Archives of General Psychiatry, 4(6), 561.
329	https://doi.org/10.1001/archpsyc.1961.01710120031004
330	Behr, C., Kamp, H., Fabian, E., Krennrich, G., Mellert, W., Peter, E., Strauss, V., Walk, T., Rietjens, I. M.
331	C. M., & van Ravenzwaay, B. (2017). Gut microbiome-related metabolic changes in plasma of
332	antibiotic-treated rats. Archives of Toxicology, 91(10), 3439–3454.
333	https://doi.org/10.1007/s00204-017-1949-2
334	Bellos, S., Skapinakis, P., Rai, D., Zitko, P., Araya, R., Lewis, G., Lionis, C., & Mavreas, V. (2016).
335	Longitudinal association between different levels of alcohol consumption and a new onset of
336	depression and generalized anxiety disorder: Results from an international study in primary
337	care. Psychiatry Research, 243, 30–34. https://doi.org/10.1016/j.psychres.2016.05.049
338	Chen, H., Nwe, PK., Yang, Y., Rosen, C. E., Bielecka, A. A., Kuchroo, M., Cline, G. W., Kruse, A. C.,
339	Ring, A. M., Crawford, J. M., & Palm, N. W. (2019). A Forward Chemical Genetic Screen
340	Reveals Gut Microbiota Metabolites That Modulate Host Physiology. Cell, 177(5), 1217-
341	1231.e18. https://doi.org/10.1016/j.cell.2019.03.036

342 Chen, J., Bai, S.-J., Li, W., Zhou, C., Zheng, P., Fang, L., Wang, H., Liu, Y., & Xie, P. (2018). Urinary 343 biomarker panel for diagnosing patients with depression and anxiety disorders. Translational 344 Psychiatry, 8(1), 192. https://doi.org/10.1038/s41398-018-0245-0 DeVido, J. J., & Weiss, R. D. (2012). Treatment of the depressed alcoholic patient. Current Psychiatry 345 346 Reports, 14(6), 610–618. https://doi.org/10.1007/s11920-012-0314-7 347 Fujisaka, S., Avila-Pacheco, J., Soto, M., Kostic, A., Dreyfuss, J. M., Pan, H., Ussar, S., Altindis, E., Li, N., 348 Bry, L., Clish, C. B., & Kahn, C. R. (2018). Diet, Genetics, and the Gut Microbiome Drive 349 Dynamic Changes in Plasma Metabolites. Cell Reports, 22(11), 3072–3086. 350 https://doi.org/10.1016/j.celrep.2018.02.060 351 Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018). Peripheral biomarkers of major depression and antidepressant treatment response: Current 352 353 knowledge and future outlooks. Journal of Affective Disorders, 233, 3-14. 354 https://doi.org/10.1016/j.jad.2017.07.001 355 García-Esquinas, E., Ortolá, R., Galán, I., Soler-Vila, H., Laclaustra, M., & Rodríguez-Artalejo, F. (2018). 356 Moderate alcohol drinking is not associated with risk of depression in older adults. Scientific 357 Reports, 8(1), 11512. https://doi.org/10.1038/s41598-018-29985-4 358 Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., 359 Smith, S. M., Huang, B., & Hasin, D. S. (2015). Epidemiology of DSM-5 Alcohol Use Disorder: 360 Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA 361 Psychiatry, 72(8), 757. https://doi.org/10.1001/jamapsychiatry.2015.0584 362 Heikkinen, N., Kärkkäinen, O., Laukkanen, E., Kekkonen, V., Kaarre, O., Kivimäki, P., Könönen, M., Velagapudi, V., Nandania, J., Lehto, S. M., Niskanen, E., Vanninen, R., & Tolmunen, T. (2019). 363 364 Changes in the serum metabolite profile correlate with decreased brain gray matter volume 365 in moderate-to-heavy drinking young adults. Alcohol, 75, 89–97. https://doi.org/10.1016/j.alcohol.2018.05.010 366

367 Jaremek, M., Yu, Z., Mangino, M., Mittelstrass, K., Prehn, C., Singmann, P., Xu, T., Dahmen, N., 368 Weinberger, K. M., Suhre, K., Peters, A., Döring, A., Hauner, H., Adamski, J., Illig, T., Spector, 369 T. D., & Wang-Sattler, R. (2013). Alcohol-induced metabolomic differences in humans. Translational Psychiatry, 3(7), e276-e276. https://doi.org/10.1038/tp.2013.55 370 371 Kärkkäinen, O., Farokhnia, M., Klåvus, A., Auriola, S., Lehtonen, M., Deschaine, S. L., Piacentino, D., 372 Abshire, K. M., Jackson, S. N., & Leggio, L. (2021). Effect of intravenous ghrelin 373 administration, combined with alcohol, on circulating metabolome in heavy drinking 374 individuals with alcohol use disorder. Alcoholism, Clinical and Experimental Research, 45(11), 375 Article 11. https://doi.org/10.1111/acer.14719 376 Kärkkäinen, O., Klåvus, A., Voutilainen, A., Virtanen, J., Lehtonen, M., Auriola, S., Kauhanen, J., & Rysä, J. (2020). Changes in circulating metabolome precede alcohol-related diseases in 377 378 middle-aged men: A prospective population-based study with a 30-year follow-up. 379 Alcoholism: Clinical and Experimental Research, 44, 2457–2467. https://doi.org/10.1111/acer.14485 380 381 Kärkkäinen, O., Kokla, M., Lehtonen, M., Auriola, S., Martiskainen, M., Tiihonen, J., Karhunen, P. J., Hanhineva, K., & Kok, E. (2021). Changes in the metabolic profile of human male 382 postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol 383 384 use. Addiction Biology, e13035. https://doi.org/10.1111/adb.13035 385 Kawase, T., Nagasawa, M., Ikeda, H., Yasuo, S., Koga, Y., & Furuse, M. (2017). Gut microbiota of mice 386 putatively modifies amino acid metabolism in the host brain. British Journal of Nutrition, 387 117(6), 775–783. https://doi.org/10.1017/S0007114517000678 Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, 388 389 K., Moloney, G., Hoban, A. E., Scott, L., Fitzgerald, P., Ross, P., Stanton, C., Clarke, G., Cryan, J. F., & Dinan, T. G. (2016). Transferring the blues: Depression-associated gut microbiota 390 induces neurobehavioural changes in the rat. Journal of Psychiatric Research, 82, 109–118. 391 392 https://doi.org/10.1016/j.jpsychires.2016.07.019

393 Kraav, S.-L., Tolmunen, T., Kärkkäinen, O., Ruusunen, A., Viinamäki, H., Mäntyselkä, P., Koivumaa-394 Honkanen, H., Valkonen-Korhonen, M., Honkalampi, K., Herzig, K.-H., & Lehto, S. M. (2019). 395 Decreased serum total cholesterol is associated with a history of childhood physical violence 396 in depressed outpatients. Psychiatry Research, 272, 326–333. 397 https://doi.org/10.1016/j.psychres.2018.12.108 398 Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, 399 V., Bäckhed, F., Verbeke, K., de Timary, P., & Delzenne, N. M. (2014). Intestinal permeability, 400 gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proceedings 401 of the National Academy of Sciences, 111(42), E4485–E4493. 402 https://doi.org/10.1073/pnas.1415174111 Lees, H. J., Swann, J. R., Wilson, I. D., Nicholson, J. K., & Holmes, E. (2013). Hippurate: The Natural 403 404 History of a Mammalian-Microbial Cometabolite. Journal of Proteome Research, 12(4), 405 1527–1546. https://doi.org/10.1021/pr300900b 406 Lehikoinen, A. I., Kärkkäinen, O. K., Lehtonen, M. A. S., Auriola, S. O. K., Hanhineva, K. J., & Heinonen, 407 S. T. (2018). Alcohol and substance use are associated with altered metabolome in the first 408 trimester serum samples of pregnant mothers. European Journal of Obstetrics & Gynecology 409 and Reproductive Biology, 223, 79-84. https://doi.org/10.1016/j.ejogrb.2018.02.004 410 Lehto, S. M., Niskanen, L., Tolmunen, T., Hintikka, J., Viinamäki, H., Heiskanen, T., Honkalampi, K., 411 Kokkonen, M., & Koivumaa-Honkanen, H. (2010). Low serum HDL-cholesterol levels are 412 associated with long symptom duration in patients with major depressive disorder: HDL-C 413 and the duration of depression. Psychiatry and Clinical Neurosciences, 64(3), 279–283. https://doi.org/10.1111/j.1440-1819.2010.02079.x 414 415 Llopis, M., Cassard, A. M., Wrzosek, L., Boschat, L., Bruneau, A., Ferrere, G., Puchois, V., Martin, J. C., 416 Lepage, P., Le Roy, T., Lefèvre, L., Langelier, B., Cailleux, F., González-Castro, A. M., Rabot, S., Gaudin, F., Agostini, H., Prévot, S., Berrebi, D., ... Perlemuter, G. (2016). Intestinal microbiota 417

418 contributes to individual susceptibility to alcoholic liver disease. Gut, 65(5), 830–839. 419 https://doi.org/10.1136/gutjnl-2015-310585 420 Lukić, I., Getselter, D., Koren, O., & Elliott, E. (2019). Role of Tryptophan in Microbiota-Induced Depressive-Like Behavior: Evidence From Tryptophan Depletion Study. Frontiers in 421 422 Behavioral Neuroscience, 13, 123. https://doi.org/10.3389/fnbeh.2019.00123 423 McHugh, R. K., & Weiss, R. D. (2019). Alcohol Use Disorder and Depressive Disorders. Alcohol 424 Research: Current Reviews, 40(1), arcr.v40.1.01. https://doi.org/10.35946/arcr.v40.1.01 425 Milstein, H. J., Bloomer, J. R., & Klatskin, G. (1976). Serum bile acids in alcoholic liver disease. 426 Comparison with histological features of the disease. The American Journal of Digestive 427 Diseases, 21(4), 281–285. https://doi.org/10.1007/BF01071839 Odlaug, B. L., Gual, A., DeCourcy, J., Perry, R., Pike, J., Heron, L., & Rehm, J. (2016). Alcohol 428 429 Dependence, Co-occurring Conditions and Attributable Burden. Alcohol and Alcoholism, 430 51(2), 201-209. https://doi.org/10.1093/alcalc/agv088 431 Pessa-Morikawa, T., Husso, A., Kärkkäinen, O., Koistinen, V., Hanhineva, K., Iivanainen, A., & Niku, M. 432 (2022). Maternal microbiota-derived metabolic profile in fetal murine intestine, brain and 433 placenta. BMC Microbiology, 22(1), 46. https://doi.org/10.1186/s12866-022-02457-6 434 Phua, L. C., Wilder-Smith, C. H., Tan, Y. M., Gopalakrishnan, T., Wong, R. K., Li, X., Kan, M. E., Lu, J., 435 Keshavarzian, A., & Chan, E. C. Y. (2015). Gastrointestinal Symptoms and Altered Intestinal 436 Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes. 437 Journal of Proteome Research, 14(11), 4734–4742. 438 https://doi.org/10.1021/acs.jproteome.5b00603 Rutledge, G. A., Sandhu, A. K., Miller, M. G., Edirisinghe, I., Burton-Freeman, B. B., & Shukitt-Hale, B. 439 440 (2021). Blueberry phenolics are associated with cognitive enhancement in supplemented 441 healthy older adults. Food & Function, 12(1), 107–118. https://doi.org/10.1039/d0fo02125c

442 Sullivan, L. E., Fiellin, D. A., & O'Connor, P. G. (2005). The prevalence and impact of alcohol problems 443 in major depression: A systematic review. The American Journal of Medicine, 118(4), 330-444 341. https://doi.org/10.1016/j.amjmed.2005.01.007 Swendsen, J. D., Merikangas, K. R., Canino, G. J., Kessler, R. C., Rubio-Stipec, M., & Angst, J. (1998). 445 446 The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Comprehensive Psychiatry, 39(4), 176-184. https://doi.org/10.1016/s0010-447 448 440x(98)90058-x 449 Trinchet, J. C., Gerhardt, M. F., Balkau, B., Munz, C., & Poupon, R. E. (1994). Serum bile acids and 450 cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. 451 Journal of Hepatology, 21(2), 235-240. https://doi.org/10.1016/s0168-8278(05)80401-5 van Sumere, C. F., Teuchy, H., Pé, H., Verbeke, R., & Bekaert, J. (1969). Quantitative investigation on 452 453 the hippuric acid formation in healthy and diseased individuals. Clinica Chimica Acta, 26(1), 454 85-88. https://doi.org/10.1016/0009-8981(69)90289-7 455 Voutilainen, T., & Kärkkäinen, O. (2019). Changes in the Human Metabolome Associated With 456 Alcohol Use: A Review. Alcohol and Alcoholism, 54(3), 225-234. 457 https://doi.org/10.1093/alcalc/agz030 Vuong, H. E., Pronovost, G. N., Williams, D. W., Coley, E. J. L., Siegler, E. L., Qiu, A., Kazantsev, M., 458 459 Wilson, C. J., Rendon, T., & Hsiao, E. Y. (2020). The maternal microbiome modulates fetal 460 neurodevelopment in mice. Nature, 586(7828), 281-286. https://doi.org/10.1038/s41586-461 020-2745-3 462 Williams, H. R., Cox, I. J., Walker, D. G., Cobbold, J. F., Taylor-Robinson, S. D., Marshall, S. E., & Orchard, T. R. (2010). Differences in gut microbial metabolism are responsible for reduced 463 464 hippurate synthesis in Crohn's disease. BMC Gastroenterology, 10(1), 108. https://doi.org/10.1186/1471-230X-10-108 465

466 Winter, G., Hart, R. A., Charlesworth, R. P. G., & Sharpley, C. F. (2018). Gut microbiome and 467 depression: What we know and what we need to know. Reviews in the Neurosciences, 29(6), 468 629–643. https://doi.org/10.1515/revneuro-2017-0072 Würtz, P., Cook, S., Wang, Q., Tiainen, M., Tynkkynen, T., Kangas, A. J., Soininen, P., Laitinen, J., 469 470 Viikari, J., Kähönen, M., Lehtimäki, T., Perola, M., Blankenberg, S., Zeller, T., Männistö, S., Salomaa, V., Järvelin, M.-R., Raitakari, O. T., Ala-Korpela, M., & Leon, D. A. (2016). Metabolic 471 472 profiling of alcohol consumption in 9778 young adults. International Journal of 473 Epidemiology, 45(5), 1493-1506. https://doi.org/10.1093/ije/dyw175 474 Yilmaz, A., Ugur, Z., Bisgin, H., Akyol, S., Bahado-Singh, R., Wilson, G., Imam, K., Maddens, M. E., & 475 Graham, S. F. (2020). Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment: A Pilot Study. 476 477 Metabolites, 10(9), E357. https://doi.org/10.3390/metabo10090357 478 Zheng, P., Chen, J., Huang, T., Wang, M., Wang, Y., Dong, M., Huang, Y., Zhou, L., & Xie, P. (2013). A 479 Novel Urinary Metabolite Signature for Diagnosing Major Depressive Disorder. Journal of 480 *Proteome Research*, 12(12), 5904–5911. https://doi.org/10.1021/pr400939a Zheng, P., Wang, Y., Chen, L., Yang, D., Meng, H., Zhou, D., Zhong, J., Lei, Y., Melgiri, N. D., & Xie, P. 481 482 (2013). Identification and validation of urinary metabolite biomarkers for major depressive 483 disorder. Molecular & Cellular Proteomics: MCP, 12(1), 207-214. 484 https://doi.org/10.1074/mcp.M112.021816 485 Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., Zhang, X., Yang, 486 D., Yang, Y., Meng, H., Li, W., Melgiri, N. D., Licinio, J., Wei, H., & Xie, P. (2016). Gut 487 microbiome remodeling induces depressive-like behaviors through a pathway mediated by 488 the host's metabolism. *Molecular Psychiatry*, 21(6), 786–796. https://doi.org/10.1038/mp.2016.44 489 Zheng, Y., Beck, O., & Helander, A. (2011). Method development for routine liquid chromatography-490 491 mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in

492 blood. Clinica Chimica Acta, 412(15-16), 1428-1435. https://doi.org/10.1016/j.cca.2011.04.022 493

494

Table 1: Background characteristics of the study cohorts.

496

497

498

499

500

	Cohort			
Variable	GP (n = 247)	MDD (n=99)	test value	p-value
Age (years, mean ±SD)	54.6 (±9.5)	39.4 (±11.9)	4213 ^b	< 0.0001
Gender (% females)	118 (48 %)	56 (56%)	2 a	0.1393
Living with a partner (n, %)	206 (83%)	52 (53%)	37 a	< 0.0001
BDI score (mean \pm SD)	3 (±2)	28 (±12)	22733 ^b	< 0.0001
Self-reported alcohol use (n, %)			13 ^a	0.0742
Light alcohol use	192 (78%)	77 (78%)		
< 1 doses/week	75 (30%)	34 (34%)		
1-2 doses/week	59 (24%)	26 (26%)		
3-5 doses/week	58 (23%)	17 (17%)		
Moderate alcohol use	54 (22%)	19 (19%)		
6-9 doses/week	26 (10%)	15 (15%)		
10-14 doses/week	23 (9%)	2 (2%)		
15-21 doses/week	5 (2%)	2 (2%)		
Heavy alcohol use	1 (0.4%)	3 (3%)		
22-28 doses/week	1 (0.4%)	2 (2%)		
>28 doses/week	0 (0%)	1 (2%)		
Smoking (n, %)	48 (19%)	33 (33%)	18 a	< 0.0001
Antidepressant use (n, %)	0 (0%)	84 (85%)	277 a	< 0.0001
BMI (mean ±SD)	28 (±5)	-		
Use of vegetables (n, %)				
>5 times/week	81 (32%)	-		
1-5 times/week	85 (34%)	-		
<1 times/week	86 (34%)	-		
Use of fruits (n, %)				
>5 times/week	95 (38%)	-		
1-5 times/week	88 (35%)	-		
<1 times/week	69 (27%)	_		

Legend: GP, general population cohort; MDD, cohort of patients with a major depressive disorder; BDI, Beck Depression Inventory; BMI, body mass index; SD, standard deviation; significant difference between the study cohorts as evaluated by: $a = \chi 2$ test, or b = MannWhitney U test.




Figure 1: Metabolites associated with self-reported alcohol use. Standardized β coefficients are shown (with 95% confidence intervals as dashed lines) for linear regression models between measured metabolites and self-reported alcohol use with negative (A) or positive (B) correlations. After correction for multiple testing, only correlations between selfreported alcohol use and chenodeoxycholic acid, hippuric acid and xanthosine can be viewed as significant (p-values below multiple testing adjusted α of 0.001). Other correlations should be considered as trends. Legend: GP, general population cohort; MDD, major depressive disorder cohort; β, standardized β coefficient from linear regression model; p, p-value from linear regression model; *, p-value < 0.001 (Bonferroni adjusted α level).

503

504

505 506

507

508

509

510